Background
Background Administration of a Administration of a complex tyrosine-free amino acid drink complex tyrosine-free amino acid drink acutely decreases manic symptoms. acutely decreases manic symptoms. Although a nutrient-based approach to Although a nutrient-based approach to illness management is attractive, complex illness management is attractive, complex amino acid drinks are too unpalatable for amino acid drinks are too unpalatable for repeated administration. repeated administration.
Aims
Aims To assess whether a simple, To assess whether a simple, branched-chain amino acid (BCAA) drink branched-chain amino acid (BCAA) drink diminishes manic symptoms acutely and diminishes manic symptoms acutely and following repeated administration. following repeated administration.
Method Method Twenty-five patients with
Twenty-five patients with mania were randomly and blindly allocated mania were randomly and blindly allocated to treatment with BCAA (60 g) or to treatment with BCAA (60 g) or placebo daily for 7 days. placebo daily for 7 days.
Results
Results Relative to placebo, the BCAA Relative to placebo, the BCAA drink lowered mania ratings acutely over drink lowered mania ratings acutely over the first 6 h of treatment.In protocol the first 6 h of treatment.In protocol completers there was a persistent completers there was a persistent advantage tothe BCAA group1week after advantagetothe BCAA group1week after the end of treatment. the end of treatment.
Conclusions Conclusions A nutritionalintervention
A nutritionalintervention that decreases tyrosine availability to the that decreases tyrosine availability to the brain acutely ameliorates manic brain acutely ameliorates manic symptoms.Further studies are required to symptoms.Further studies are required to assess whether this approach has longerassess whether this approach has longerterm efficacy. term efficacy.
Declaration of interest Declaration of interest This study
This study was funded by the WellcomeTrust; P.J.C. was funded by the WellcomeTrust; P.J.C. In experimental studies in animals, acute In experimental studies in animals, acute administration of an amino acid mixture administration of an amino acid mixture lacking the catecholamine precursors lacking the catecholamine precursors tyrosine and phenylalanine (tyrosine-free) tyrosine and phenylalanine (tyrosine-free) decreases the availability of plasma tyrosine decreases the availability of plasma tyrosine to the brain. This diminishes catecholamine to the brain. This diminishes catecholamine synthesis and attenuates the dopaminesynthesis and attenuates the dopaminereleasing properties of amphetamine releasing properties of amphetamine (McTavish (McTavish et al et al, 1999) . Similarly, in , 1999) . Similarly, in humans, administration of a tyrosine-free humans, administration of a tyrosine-free amino acid load attenuates both subjective amino acid load attenuates both subjective and objective effects of methamphetamine and objective effects of methamphetamine in healthy volunteers (McTavish in healthy volunteers (McTavish et al et al, , 2001 ). The ability of amphetamine to 2001). The ability of amphetamine to release dopamine has been linked to its psyrelease dopamine has been linked to its psychostimulant effects, making it a plausible chostimulant effects, making it a plausible model of mania (Jacobs & Silverstone, model of mania (Jacobs & Silverstone, 1986) . A preliminary study in people with 1986). A preliminary study in people with mania showed that a single dose of the mania showed that a single dose of the tyrosine-free amino acid load acutely tyrosine-free amino acid load acutely decreased symptom severity on an observerdecreased symptom severity on an observerrated clinical scale over 6 h (McTavish rated clinical scale over 6 h (McTavish et et al al, 2001 ). However, the amino acid drink , 2001). However, the amino acid drink used was unpalatable and unsuitable for used was unpalatable and unsuitable for the repeated administration required in the repeated administration required in the treatment of clinical disorders. the treatment of clinical disorders.
In our study we used a simpler amino In our study we used a simpler amino acid mixture containing only three acid mixture containing only three branched-chain amino acids (BCAAs): leubranched-chain amino acids (BCAAs): leucine, isoleucine and valine. These amino cine, isoleucine and valine. These amino acids compete with phenylalanine and tyroacids compete with phenylalanine and tyrosine for brain entry, and studies in healthy sine for brain entry, and studies in healthy volunteers indicate that BCAAs produce volunteers indicate that BCAAs produce cognitive and endocrine effects consistent cognitive and endocrine effects consistent with attenuation of central dopamine with attenuation of central dopamine neurotransmission (Gijsman neurotransmission (Gijsman et al et al, 2002) . , 2002). In addition, the BCAA drink is palatable, In addition, the BCAA drink is palatable, safe and well tolerated during longer-term safe and well tolerated during longer-term ingestion (Richardson ingestion (Richardson et al et al, 1999) . The , 1999) . The effect of the BCAA drink on manic sympeffect of the BCAA drink on manic symptoms was assessed both acutely and after toms was assessed both acutely and after repeated administration. repeated administration.
METHOD METHOD

General study design General study design
We compared a drink containing BCAAs We compared a drink containing BCAAs with a placebo drink for the treatment of with a placebo drink for the treatment of acute mania. This intervention was added acute mania. This intervention was added to treatment as usual, lasted for 7 days to treatment as usual, lasted for 7 days and was followed by a 7-day follow-up and was followed by a 7-day follow-up period. The protocol was approved by period. The protocol was approved by the local ethics committee and all particithe local ethics committee and all participants gave informed consent before pants gave informed consent before randomisation. randomisation.
Participants Participants
Patients participating in the study fulfilled Patients participating in the study fulfilled DSM-IV criteria for bipolar I disorder with DSM-IV criteria for bipolar I disorder with a current manic episode (American Psychia current manic episode (American Psychiatric Association, 1994) and were assessed atric Association, 1994) and were assessed to have a score of 20 or more on the Young to have a score of 20 or more on the Young Mania Rating Scale (YMRS; Young Mania Rating Scale (YMRS; Young et al et al, , 1978) . These patients were recruited from 1978). These patients were recruited from five acute wards within the Oxfordshire five acute wards within the Oxfordshire Mental Healthcare National Health Service Mental Healthcare National Health Service Trust. The main exclusion criteria were serTrust. The main exclusion criteria were serious physical illness and the inability to give ious physical illness and the inability to give informed consent in the opinion of either informed consent in the opinion of either the ward consultant or the investigators. the ward consultant or the investigators. We also excluded patients who were taking We also excluded patients who were taking sodium valproate, because both valproate sodium valproate, because both valproate and BCAA may have hepatotoxic effects and BCAA may have hepatotoxic effects and we did not wish to risk a possible and we did not wish to risk a possible interaction. interaction.
Intervention Intervention
Each patient received a drink containing Each patient received a drink containing 60 g amino acid or a seemingly identical 60 g amino acid or a seemingly identical placebo. The experimental mixture conplacebo. The experimental mixture consisted of valine, isoleucine and leucine in sisted of valine, isoleucine and leucine in the ratio 3:3:4. The control drink contained the ratio 3:3:4. The control drink contained fatty flakes to simulate the texture of the fatty flakes to simulate the texture of the experimental mixture. Both drinks also experimental mixture. Both drinks also contained flavouring, peanut oil and water, contained flavouring, peanut oil and water, as described elsewhere (Gijsman as described elsewhere (Gijsman et al et al, , 2002; Scarna 2002; Scarnà et al et al, 2002) . All drinks were , 2002). All drinks were prepared and administered by a research prepared and administered by a research nurse not involved in the further execution nurse not involved in the further execution of the study. Prescribed medication and of the study. Prescribed medication and food were not withheld during the study food were not withheld during the study period. The drink was administered once period. The drink was administered once daily in the morning. daily in the morning.
Objectives Objectives
To assess the tolerability and effect of a To assess the tolerability and effect of a drink containing BCAAs compared with drink containing BCAAs compared with placebo on the symptoms of acute mania, placebo on the symptoms of acute mania, specifically over 6 h after the first drink as specifically over 6 h after the first drink as well as during and after a treatment period well as during and after a treatment period of 7 days. of 7 days.
Outcomes Outcomes
The YMRS was used as the sample selecThe YMRS was used as the sample selection tool. Our outcome measure was the tion tool. Our outcome measure was the Beigel Manic State Rating Scale, which is Beigel Manic State Rating Scale, which is sensitive to clinical changes over short sensitive to clinical changes over short 21 0 21 0 periods and reflects a wider spectrum of periods and reflects a wider spectrum of symptoms (Beigel & Murphy, 1971; symptoms (Beigel & Murphy, 1971; McTavish McTavish et al et al, 2001) . Participants were , 2001). Participants were assessed immediately before administration assessed immediately before administration of the first drink and then hourly for 6 h. of the first drink and then hourly for 6 h. Subsequent ratings were carried out on Subsequent ratings were carried out on days 4 and 8, and 1 week after the end days 4 and 8, and 1 week after the end of treatment on day 15, after a 1-h of treatment on day 15, after a 1-h observation period and interview. observation period and interview.
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Sample size Sample size
A single dose of a tyrosine-free amino acid A single dose of a tyrosine-free amino acid drink reduced manic symptoms by 35% in drink reduced manic symptoms by 35% in a similar study with group size of 10 a similar study with group size of 10 (McTavish (McTavish et al et al, 2001) . For the study de-, 2001) . For the study described here we aimed at a similar effect scribed here we aimed at a similar effect after a single dose and therefore required after a single dose and therefore required a group size of at least 10. For the 15-day a group size of at least 10. For the 15-day follow-up we aimed at 10 completers in follow-up we aimed at 10 completers in each group. each group.
Randomisation Randomisation
An independent investigator generated a An independent investigator generated a randomisation sequence on a computer. randomisation sequence on a computer. Randomisation was calculated in blocks Randomisation was calculated in blocks of four. Allocation was concealed by using of four. Allocation was concealed by using numbered and weight-balanced boxes connumbered and weight-balanced boxes containing all the ingredients for the treatment taining all the ingredients for the treatment of one patient. The independent supplier of of one patient. The independent supplier of the ingredients prepared these boxes. Pathe ingredients prepared these boxes. Patients included in the study were given a tients included in the study were given a sequential number and the corresponding sequential number and the corresponding box was opened by the independent rebox was opened by the independent research nurse when preparing the first drink. search nurse when preparing the first drink.
Masking Masking
Participants and investigators were masked Participants and investigators were masked to group assignment. The success of to group assignment. The success of masking was not separately assessed. masking was not separately assessed.
Statistical methods Statistical methods
For the single dose study, Beigel scores were For the single dose study, Beigel scores were analysed as change from baseline and comanalysed as change from baseline and compared using a repeated-measures analysis of pared using a repeated-measures analysis of variance (ANOVA) with 'time' (time of ratvariance (ANOVA) with 'time' (time of rating) as the within-subject factor and 'drink' ing) as the within-subject factor and 'drink' (BCAA or placebo) as the between-subject (BCAA or placebo) as the between-subject factor. For the 15-day follow-up the Beigel factor. For the 15-day follow-up the Beigel scores were also analysed as change from scores were also analysed as change from baseline. Repeated-measures ANOVAs baseline. Repeated-measures ANOVAs were conducted with 'day' (day of rating) were conducted with 'day' (day of rating) as the main within-subject factor and as the main within-subject factor and 'drink' (BCAA or placebo) as the between-'drink' (BCAA or placebo) as the betweensubject factor. For all ANOVAs, uncorsubject factor. For all ANOVAs, uncorrected degrees of freedom are reported rected degrees of freedom are reported for reasons of clarity, but Huynh-Feldt for reasons of clarity, but Huynh-Feldt correction was used. All correction was used. All t t-tests are reported -tests are reported with equal variances not assumed. with equal variances not assumed.
RESULTS RESULTS
Participant flow Participant flow
Recruitment took place between January Recruitment took place between January and December 2001. Forty-nine patients and December 2001. Forty-nine patients considered suitable were screened. Of considered suitable were screened. Of these, 13 patients scored below 20 on the these, 13 patients scored below 20 on the YMRS, 1 was unable to provide informed YMRS, 1 was unable to provide informed consent, 3 were taking sodium valproate consent, 3 were taking sodium valproate and 6 refused to participate. One further and 6 refused to participate. One further patient was unsuitable for other clinical patient was unsuitable for other clinical reasons. The remaining 25 patients were reasons. The remaining 25 patients were randomised. Thirteen participants received randomised. Thirteen participants received the BCAA drink and 12 were given the plathe BCAA drink and 12 were given the placebo. Seven participants discontinued the cebo. Seven participants discontinued the allocated treatment: 4 after day 1, and 3 allocated treatment: 4 after day 1, and 3 after day 2. Two participants in the placebo after day 2. Two participants in the placebo group were withdrawn from the study for group were withdrawn from the study for clinical reasons, unrelated to the drink. Of clinical reasons, unrelated to the drink. Of the five who withdrew from the BCAA the five who withdrew from the BCAA group, one complained of sleepiness and group, one complained of sleepiness and another of nausea, both possibly related another of nausea, both possibly related to the drink. Another participant cited conto the drink. Another participant cited concern about protein as a reason for not comcern about protein as a reason for not completing the study, and a fourth expressed pleting the study, and a fourth expressed some paranoid ideas regarding contents of some paranoid ideas regarding contents of the drink. The fifth participant did not give the drink. The fifth participant did not give a reason for discontinuing. Eighteen particia reason for discontinuing. Eighteen participants (8 BCAA, 10 placebo) completed the pants (8 BCAA, 10 placebo) completed the treatment protocol. There was no drop-out treatment protocol. There was no drop-out from follow-up and all 25 participants were from follow-up and all 25 participants were assessed up to day 15. assessed up to day 15.
Baseline data Baseline data
Patients were aged 19-62 years (mean 41 Patients were aged 19-62 years (mean 41 years). Three patients were experiencing a years). Three patients were experiencing a first episode of mania; the others had a first episode of mania; the others had a mean of 2 previous hospital admissions mean of 2 previous hospital admissions for manic illness (range 1 to 4). The for manic illness (range 1 to 4). The medication used for each patient was left medication used for each patient was left to the discretion of the psychiatrist. to the discretion of the psychiatrist. Twenty-two patients were receiving antiTwenty-two patients were receiving antipsychotic medication during the study. psychotic medication during the study. Nine of these participants were also receivNine of these participants were also receiving treatment with a mood stabiliser: 5 ing treatment with a mood stabiliser: 5 were receiving carbamazepine, and 4 were were receiving carbamazepine, and 4 were receiving lithium. Mood stabiliser monoreceiving lithium. Mood stabiliser monotherapy had not failed in this group of patherapy had not failed in this group of patients; rather, the standard treatment for tients; rather, the standard treatment for most of the consultant psychiatrists was most of the consultant psychiatrists was an antipsychotic plus a benzodiazepine. an antipsychotic plus a benzodiazepine. Of the remaining 3 participants, 1 was takOf the remaining 3 participants, 1 was taking lithium only, 1 carbamazepine only and ing lithium only, 1 carbamazepine only and 1 both drugs combined. 1 both drugs combined.
Fifteen of the participants received inFifteen of the participants received intermittent treatment with benzodiazepines. termittent treatment with benzodiazepines. In the placebo group, 5 patients were takIn the placebo group, 5 patients were taking lorazepam and 1 patient was taking zoing lorazepam and 1 patient was taking zopiclone. One patient had taken lorazepam piclone. One patient had taken lorazepam on one occasion before being changed to on one occasion before being changed to zopiclone. In the BCAA group, 5 patients zopiclone. In the BCAA group, 5 patients were taking lorazepam, 2 clonazepam and were taking lorazepam, 2 clonazepam and 1 diazepam. When converted to diazepam 1 diazepam. When converted to diazepam equivalents, there was little difference beequivalents, there was little difference between the average amounts taken at the tween the average amounts taken at the start of the study (5.4 mg for the placebo start of the study (5.4 mg for the placebo group, 6.5 mg for the BCAA group) and group, 6.5 mg for the BCAA group) and this did not differ significantly throughout this did not differ significantly throughout the duration of the study. the duration of the study.
The mean score on the YMRS was 29 The mean score on the YMRS was 29 (range 21-42), within the range of that seen (range 21-42), within the range of that seen in drug treatment studies of mania (Tohen in drug treatment studies of mania (Tohen et al et al, 2000) . The two groups (BCAA , 2000) . The two groups (BCAA v v. pla-. placebo) were well matched for baseline severcebo) were well matched for baseline severity of manic symptoms on the YMRS: 29. 
Numbers analysed Numbers analysed
All 25 participants received the allocated All 25 participants received the allocated intervention on day 1 of the study. These intervention on day 1 of the study. These participants completed all follow-up meaparticipants completed all follow-up measurements and were included in the surements and were included in the intention-to-treat analysis. Additionally, intention-to-treat analysis. Additionally, we analysed data from the 18 participants we analysed data from the 18 participants who received the full 7 days of treatment. who received the full 7 days of treatment.
Outcomes Outcomes
Administration of the BCAA drink on day 1 Administration of the BCAA drink on day 1 significantly reduced clinical ratings of significantly reduced clinical ratings of mania as measured by change from baseline mania as measured by change from baseline on the Beigel scale relative to the placebo on the Beigel scale relative to the placebo drink (Fig. 1) . A two-way ANOVA showed drink (Fig. 1) . A two-way ANOVA showed 211 211 
02). Post hoc
Post hoc testing showed testing showed significant differences between BCAA significant differences between BCAA and control drinks at three time points and control drinks at three time points (Fig. 1) . (Fig. 1) .
Over the subsequent 2 weeks both Over the subsequent 2 weeks both treatment groups showed a fall in clinical treatment groups showed a fall in clinical ratings of mania on the intention-to-treat ratings of mania on the intention-to-treat analysis (Fig. 2) . The ANOVA showed a analysis (Fig. 2) . The ANOVA showed a significant effect of day ( significant effect of day (F F¼13.81 1,16 ¼7.5, 7.5, P P5 50.01). The placebo 0.01). The placebo effect diminished during the week of treateffect diminished during the week of treatment, whereas the BCAA group continued ment, whereas the BCAA group continued to improve (Fig. 3) . to improve (Fig. 3) .
Adverse events Adverse events
The BCAA drink was generally well tolerThe BCAA drink was generally well tolerated over the period of the study and the ated over the period of the study and the majority of the patients had no problem majority of the patients had no problem in swallowing it. The only substantial in swallowing it. The only substantial adverse effects were reported by the two adverse effects were reported by the two participants in the BCAA group who disparticipants in the BCAA group who discontinued the treatment because of nausea continued the treatment because of nausea or tiredness. or tiredness.
DISCUSSION DISCUSSION
Acute effects of branched-chain Acute effects of branched-chain amino acids on manic symptoms amino acids on manic symptoms
The finding that acute administration of the The finding that acute administration of the BCAA drink decreased ratings of mania is BCAA drink decreased ratings of mania is consistent with our earlier observation with consistent with our earlier observation with a more-complex tyrosine-free amino acid a more-complex tyrosine-free amino acid mixture (McTavish mixture (McTavish et al et al, 2001) and , 2001 ) and suggests that BCAA administration might suggests that BCAA administration might be a viable way of attenuating dopabe a viable way of attenuating dopaminergic overactivity in pathological states. minergic overactivity in pathological states. It is of additional interest that in this It is of additional interest that in this study the control drink was a true placebo. study the control drink was a true placebo. Our original study employed a 'balanced' Our original study employed a 'balanced' drink containing substantial doses of tyrodrink containing substantial doses of tyrosine, making it possible that the difference sine, making it possible that the difference in effects simply reflected a contrast in effects simply reflected a contrast between a high-tyrosine and low-tyrosine between a high-tyrosine and low-tyrosine state. For example, a recent study in volunstate. For example, a recent study in volunteers suggests that a tyrosine-containing teers suggests that a tyrosine-containing drink can increase alertness (Grevet drink can increase alertness (Grevet et al et al, , 2002 (Grevet et al et al, , ). 2002 .
In fact, it is possible that the BCAA In fact, it is possible that the BCAA drink is less effective than the full drink is less effective than the full tyrosine-free amino acid mixture in acutely tyrosine-free amino acid mixture in acutely reducing the symptoms of mania. In the reducing the symptoms of mania. In the current study the people treated with BCAA current study the people treated with BCAA showed a decrease in ratings on the Beigel showed a decrease in ratings on the Beigel scale that was about 20% greater than that scale that was about 20% greater than that of the placebo group. This is somewhat less of the placebo group. This is somewhat less than the 35% reduction in symptoms seen than the 35% reduction in symptoms seen in our previous study (McTavish in our previous study (McTavish et al et al, , 2001 ). One possible explanation for this 2001). One possible explanation for this lesser effect is that the BCAA drink used lesser effect is that the BCAA drink used by McTavish by McTavish et al et al might have been less might have been less active at lowering brain tyrosine availabilactive at lowering brain tyrosine availability, because the full tyrosine-free amino ity, because the full tyrosine-free amino acid mixture lowers plasma tyrosine conacid mixture lowers plasma tyrosine concentrations as well as decreasing its brain centrations as well as decreasing its brain entry by competition at the blood-brain entry by competition at the blood-brain barrier. In contrast, the BCAA drink used barrier. In contrast, the BCAA drink used in the current study would be expected to in the current study would be expected to lower brain tyrosine by competition only lower brain tyrosine by competition only (Gijsman (Gijsman et al et al, 2002) . , 2002). Another possibility Another possibility is that the tyrosineis that the tyrosine-containing control containing control amino acid mixture used in our previous amino acid mixture used in our previous study could have caused some activation study could have caused some activation (Grevet (Grevet et al et al, 2002) , lowering the placebo , 2002), lowering the placebo response and inflating the apparent effect response and inflating the apparent effect of the tyrosine-free mixture. of the tyrosine-free mixture.
Longer-term effects Longer-term effects
Both patient groups showed an amelioraBoth patient groups showed an amelioration of symptoms over the 2-week period, tion of symptoms over the 2-week period, with most measures yielding significant with most measures yielding significant effects of day, but not of drink. This is effects of day, but not of drink. This is not surprising since routine treatment was not surprising since routine treatment was not controlled and patients continued to not controlled and patients continued to receive both routine and 'as required' medireceive both routine and 'as required' medication on the usual basis of perceived cation on the usual basis of perceived clinical need. An intention-to-treat analysis clinical need. An intention-to-treat analysis failed to differentiate placebo from the failed to differentiate placebo from the BCAA treatment, but despite the power BCAA treatment, but despite the power limitations of such a small study, there were limitations of such a small study, there were hints of additional benefit in the BCAA hints of additional benefit in the BCAA group. For example, 4 of the 8 BCAA group. For example, 4 of the 8 BCAA patients were discharged before day 15, patients were discharged before day 15, compared with only 2 from the 10 in the compared with only 2 from the 10 in the placebo group. placebo group.
When the results from the study comWhen the results from the study completers (participants who accepted the full pleters (participants who accepted the full treatment protocol) were assessed, there aptreatment protocol) were assessed, there appeared to be a waning of the symptomatic peared to be a waning of the symptomatic improvement in the placebo group after improvement in the placebo group after treatment cessation, but a continued imtreatment cessation, but a continued improvement in the BCAA group participants provement in the BCAA group participants which was statistically significant on day which was statistically significant on day 15. The reason why the BCAA group 15. The reason why the BCAA group should have continued to improve after should have continued to improve after the end of treatment is not clear. It is possthe end of treatment is not clear. It is possible that an adjunctive effect of the drink ible that an adjunctive effect of the drink for 1 week allowed a more rapid resolution for 1 week allowed a more rapid resolution of the manic syndrome even after BCAA of the manic syndrome even after BCAA treatment ended. In contrast, the placebo treatment ended. In contrast, the placebo improvement seemed to wane as would be improvement seemed to wane as would be expected. expected. 
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M Mechanism of action of echanism of action of branched-chain amino acids branched-chain amino acids
Acute BCAA treatment increases plasma Acute BCAA treatment increases plasma prolactin levels and impairs performance prolactin levels and impairs performance on a spatial recognition task, effects consison a spatial recognition task, effects consistent with attenuation of dopamine neurotent with attenuation of dopamine neurotransmission (Gijsman transmission (Gijsman et al et al, 2002) . In , 2002). In addition, using positron emission tomograaddition, using positron emission tomography we have found that a full tyrosine-free phy we have found that a full tyrosine-free amino acid mixture increases striatal bindamino acid mixture increases striatal binding of the dopamine receptor ligand ing of the dopamine receptor ligand [ [ Although we believe that there is now Although we believe that there is now strong evidence that the BCAA mixture strong evidence that the BCAA mixture impairs dopamine release for the first impairs dopamine release for the first few hours after administration, we do few hours after administration, we do not know for how long this effect persists not know for how long this effect persists and whether it is maintained after and whether it is maintained after repeated treatment. We decided to repeated treatment. We decided to administer the BCAA drink once daily administer the BCAA drink once daily to increase compliance, but it is possible to increase compliance, but it is possible that more-frequent daily treatment would that more-frequent daily treatment would have produced a better effect. However, have produced a better effect. However, administration of BCAAs at high dosage administration of BCAAs at high dosage carries potential risks such as increased carries potential risks such as increased plasma ammonia concentration hepatoplasma ammonia concentration hepatotoxicity. In a study in healthy volunteers toxicity. In a study in healthy volunteers we monitored plasma ammonia levels we monitored plasma ammonia levels after a drink containing 60 g BCAA, and after a drink containing 60 g BCAA, and found that although plasma ammonia found that although plasma ammonia concentrations were elevated over 6 h, concentrations were elevated over 6 h, the average maximum elevation the average maximum elevation (52 (52 m mmol/l) was below toxic plasma levels mol/l) was below toxic plasma levels ( (4 480 80 m mmol/l) (Scarna mol/l) (Scarnà et al et al, 2001) . How-, 2001 ). However, higher doses or longer-term use of ever, higher doses or longer-term use of BCAA treatment might require liver BCAA treatment might require liver function test monitoring. function test monitoring.
Possible therapeutic utility Possible therapeutic utility
Taken together, our findings suggest that Taken together, our findings suggest that the BCAA drink is a useful and wellthe BCAA drink is a useful and welltolerated tool for modifying dopaminergic tolerated tool for modifying dopaminergic function. Although it may be unrealistic to function. Although it may be unrealistic to expect such a dietary manipulation to be expect such a dietary manipulation to be as potent as an antipsychotic drug, the as potent as an antipsychotic drug, the BCAA drink does appear to achieve an BCAA drink does appear to achieve an acute reduction in symptoms in patients acute reduction in symptoms in patients with mania. Indications of a more persiswith mania. Indications of a more persistent effect in speeding symptom resolution tent effect in speeding symptom resolution will need to be explored in future longerwill need to be explored in future longerterm trials. term trials.
Young, R. C., Biggs, J. T., Ziegler,V. E., Young, R. C., Biggs, J. T., Ziegler,V. E., et al et al (1978) 
A rating scale for mania: reliability, validity and A rating scale for mania: reliability, validity and sensitivity. sensitivity. The number of patients studied was small and the follow-up period short.
& & The effect of BCAA treatment to improve symptom ratings at 15 days was not The effect of BCAA treatment to improve symptom ratings at 15 days was not apparent in the intention-to-treat sample. apparent in the intention-to-treat sample.
